We are continuing the momentum from our positive phase 1 trial results and are pleased to have recently released our latest updates in our April Investor Newsletter covering:
🔹 Clinical data and expert review triggers commercial partner outreach efforts
🔹 MRI utility drives new IP and AI/ML efforts
🔹 Upcoming events and a recap on key media coverage
Read the full newsletter: HERE >>
Questions about this announcement or other investor-related inquiries? Please email our investor relations department at: investor@imagionbio.com.
